(MedPage Today) — CHICAGO — An investigational individualized vaccine for surgically resected melanoma demonstrated durable benefits in reducing the risks of recurrence and distant spread, 5-year follow-up of a randomized study showed.
Adding…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
